Retrospective Study of the Prevalence, Histopathology, Therapy, and Survival Time of Neoplastic Disease in Fish.
Emma FerraroScott H HarrisonElizabeth G DukeBrigid V TroanAmy BoddyLisa M AbegglenTara M HarrisonPublished in: Animals : an open access journal from MDPI (2024)
This study evaluated neoplasia in fish using medical records from zoos, aquariums, and exotic animal veterinarians. The parameters evaluated included geographic location, habitat type, signalment, anatomic location of neoplasia, type of neoplasia as confirmed with histologic examination, survival time, and treatments provided for each patient. These data were entered into the Exotic Species Cancer Research Alliance (ESCRA) database. Out of 455 cases from across the United States and England, most animals submitted were from zoologic parks or aquariums (62.9%), followed by private ownership (1.5%). The percent of female (19.3%) and male (17.8%) patients were similar, and the mean age at the time of diagnosis was 99.45 months, with a range of 12 to 300 months. The species with the highest neoplasia prevalence was koi (18.5%), followed by goldfish (10.8%). The eye was the most commonly reported site for a primary neoplasm (8.4%), and the most prevalent diagnosis across all organ systems was soft tissue sarcoma (26.2%). Only 13 patients in this study (2.9%) received any form of treatment, with a mean survival time of 8.85 months post-treatment. These data demonstrate that while information related to clinical therapy of cancer in fish species is lacking, surgical excision of tumors in fish, when feasible for the patient and client, may improve patient outcomes.
Keyphrases
- end stage renal disease
- high grade
- newly diagnosed
- ejection fraction
- chronic kidney disease
- risk factors
- healthcare
- peritoneal dialysis
- electronic health record
- prognostic factors
- papillary thyroid
- case report
- big data
- patient reported outcomes
- squamous cell carcinoma
- stem cells
- mesenchymal stem cells
- replacement therapy
- free survival
- health insurance
- data analysis
- artificial intelligence
- health information
- combination therapy
- lymph node metastasis
- cell therapy